Literature DB >> 31060994

Advances in psychometric tests for screening minimal hepatic encephalopathy: From paper-and-pencil to computer-aided assessment.

Ming Luo1, Ping Ma2, Lei Li2, Wu-Kui Cao3.   

Abstract

Minimal hepatic encephalopathy (MHE) is a major neuropsychiatric complication of liver cirrhosis and portosystemic shunting. Although MHE produces a spectrum of cognitive impairments in the domains of short-term attention, working memory, and executive function, it generally does not present with obvious clinical manifestation on conventional assessments. Paper-and-pencil psychometric tests, such as the psychometric hepatic encephalopathy score and the repeatable battery for the assessment of neuropsychological status, are recommended to diagnose MHE. However, these tests are neither rapid nor convenient to use in practice. To facilitate repeated testing in clinic and follow-up, computer-aided psychometric tests, such as the scan test, Cognitive Drug Research assessment battery, inhibitory control test, EncephalApp Stroop App, and critical flicker frequency, have been used to screen for MHE among patients with liver cirrhosis. The aim of this review was to describe the progression from the utility of paper-and-pencil to computer-aided psychometric tests for MHE screening in clinical practice.

Entities:  

Mesh:

Year:  2019        PMID: 31060994      PMCID: PMC6505643          DOI: 10.5152/tjg.2019.18226

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  68 in total

Review 1.  Neuropsychological characterization of hepatic encephalopathy.

Authors:  K Weissenborn; J C Ennen; H Schomerus; N Rückert; H Hecker
Journal:  J Hepatol       Date:  2001-05       Impact factor: 25.083

2.  Critical flicker frequency for quantification of low-grade hepatic encephalopathy.

Authors:  Gerald Kircheis; Matthias Wettstein; Lars Timmermann; Alfons Schnitzler; Dieter Häussinger
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

3.  Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease.

Authors:  Daniel M Forton; Howard C Thomas; Christine A Murphy; Joanna M Allsop; Graham R Foster; Janice Main; Keith A Wesnes; Simon D Taylor-Robinson
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

4.  Right hemispheric dominance of inhibitory control: an event-related functional MRI study.

Authors:  H Garavan; T J Ross; E A Stein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

5.  Neuropsychological aspects of portal-systemic encephalopathy.

Authors:  H Schomerus; W Hamster
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

6.  Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests.

Authors:  P Amodio; F Del Piccolo; P Marchetti; P Angeli; R Iemmolo; L Caregaro; C Merkel; G Gerunda; A Gatta
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

7.  Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

Authors:  I McKeith; T Del Ser; P Spano; M Emre; K Wesnes; R Anand; A Cicin-Sain; R Ferrara; R Spiegel
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

8.  Inhibitory control in children with traumatic brain injury (TBI) and children with attention deficit/hyperactivity disorder (ADHD).

Authors:  K Konrad; S Gauggel; A Manz; M Schöll
Journal:  Brain Inj       Date:  2000-10       Impact factor: 2.311

9.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

10.  Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system.

Authors:  K A Wesnes; I G McKeith; R Ferrara; M Emre; T Del Ser; P F Spano; A Cicin-Sain; R Anand; R Spiegel
Journal:  Dement Geriatr Cogn Disord       Date:  2002       Impact factor: 2.959

View more
  7 in total

1.  Brain-derived neurotrophic factor as a potential diagnostic marker in minimal hepatic encephalopathy.

Authors:  Agnieszka Stawicka; Magdalena Świderska; Justyna Zbrzeźniak; Natalia Sołowianowicz; Aleksandra Woszczenko; Robert Flisiak; Jerzy Jaroszewicz
Journal:  Clin Exp Hepatol       Date:  2021-02-02

Review 2.  Cognition-tracking-based strategies for diagnosis and treatment of minimal hepatic encephalopathy.

Authors:  Weijia Han; Huanqian Zhang; Ying Han; Zhongping Duan
Journal:  Metab Brain Dis       Date:  2020-06-03       Impact factor: 3.584

Review 3.  Hepatic Encephalopathy: Diagnosis and Management.

Authors:  Lorenzo Ridola; Jessica Faccioli; Silvia Nardelli; Stefania Gioia; Oliviero Riggio
Journal:  J Transl Int Med       Date:  2020-12-31

4.  Feasibility of a novice electronic psychometric assessment system for cognitively impaired.

Authors:  Haemi Jee; Jaehyun Park
Journal:  J Exerc Rehabil       Date:  2020-12-28

Review 5.  Minimal hepatic encephalopathy - diagnosis and treatment.

Authors:  Wojciech Pisarek
Journal:  Prz Gastroenterol       Date:  2021-12-08

6.  Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis.

Authors:  Jian Fu; Yi Gao; Li Shi
Journal:  PLoS One       Date:  2022-04-26       Impact factor: 3.240

7.  Retention enema with traditional Chinese medicine for hepatic encephalopathy: A protocol for a systematic review and meta-analysis.

Authors:  Xiao Liang; Lihong Wen; Yifang Wu; Yanmin Hao; Shaobo Wang; Xiaoyu Hu
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.